Ophthalmic Drugs Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3200/- USD | Published Date: October 14, 2020 |

The global ophthalmic drugs market size is accounted for around USD 30 billion in 2019 and projected to grow at the CAGR of 5.9% market during the forecast period 2020-2027. Globally, the average life expectancy has been increasing and its posturing medical issues within the ophthalmology field are being strongly reflected. Among the elderly population, loss of eyesight is a major health problem. The growing prevalence of eye disorders has created a huge market for ophthalmic drugs. Moreover, new technologies combining drugs and device therapies are contributing significantly towards the development of the ophthalmic drugs market.

Market Insights:

The key factors responsible for the growth of the drug market are the aging population and the rising prevalence of ophthalmic disorders. In the base year 2019, prescription ophthalmic drugs are anticipated to hold the largest revenue share in the ophthalmic drugs market due to the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Glaucoma ophthalmic drugs held the largest share in the therapeutic market segment due to a large patient pool suffering from ophthalmic disorders, early diagnosis, and treatment. The ophthalmic drugs market is currently dominated by North America due to the increasing prevalence of ophthalmic disorders, favorable reimbursement scenario, and developed healthcare infrastructure. The Asia Pacific will be the fastest-growing market due to the aging population, the large number of ophthalmic surgeries performed, and rapid development in the healthcare infrastructure.

Market Segment Insights:

The global ophthalmic drugs market is segmented by prescription types such as (prescription ophthalmic drugs, and over-the-counter drugs). The prescription ophthalmic drugs segment is anticipated to hold the largest market in the ophthalmic drugs market during the forecast period. The prime factor that would determine the growth of the prescription drugs segment includes the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Moreover, the increasing rate of success for newly launched drugs which can only be bought by prescriptions would further assist the market growth. The therapeutic segment consists of (glaucoma ophthalmic drugs, retinal disorder ophthalmic drugs, dry eye ophthalmic drugs, and allergic conjunctivitis). Glaucoma ophthalmic drugs held the largest share in the global ophthalmic drugs market due to a large patient pool suffering from ophthalmic disorders, early diagnosis, and treatment.

Global Ophthalmic Drugs Market Segmentation:

By Prescription, 2018–2027 ($ Million)

  • Prescription Ophthalmic Drugs
  • Over-the-counter (OTC) Drugs

By Therapeutics, 2018–2027 ($ Million)

  • Glaucoma Ophthalmic Drugs
  • Retinal Disorder Ophthalmic Drugs
  • Dry Eye Ophthalmic Drugs
  • Allergic Conjunctivitis

By Geography, 2018-2027 ($ Million)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa, and Asia Pacific, markets together form the major regional markets for ophthalmic drug products. These regional markets are further sub-segmented into country-specific markets on the basis of demand and market growth of the ophthalmic drugs market. Among the considered regional markets, North America currently dominates the global ophthalmic drugs market, with the United States being the largest country-level market. The drivers for the North America market are a significant patient pool, early disease diagnosis and treatment, and favorable reimbursement policies. Additionally, Asia Pacific is anticipated to be the fastest-growing market for the geriatric population, rising investments in healthcare infrastructure and increasing prevalence of ocular diseases, which includes disorders of both the cornea and the retina.

Market Competition Assessment:

The major players currently operating in the global ophthalmic drugs market include Abbott healthcare, Allergan plc, Johnson and Johnson, Bayer, Novartis AG, Glaxosmithkline, Eyegate pharmaceuticals, LPath, Senten pharmaceuticals Co. Ltd., Cipla pharmaceuticals, Sun pharmaceutical industries, Ltd. and other notable players.

List of Key Companies:

  • Abbott Healthcare
  • Allergan Plc
  • Akorn
  • Bayer Johnson & Johnson
  • Cipla Pharmaceuticals Bayer
  • Eyemed
  • Eyegate Pharmaceuticals
  • Johnson & Johnson
  • LPath
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc.
  • Senju Pharmaceutical Co., Ltd
  • Senten Pharmaceutical Co. Ltd
  • Sun Pharmaceutical Industries, Ltd.
  • Valeant Pharmaceuticals, Inc.

Key Questions Answered by Ophthalmic Drugs Market Report

  • Global ophthalmic drugs market forecasts from 2020-2027
  • Regional ophthalmic drugs market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
  • Country level forecasts from 2020-2027 covering 15 major countries from the aforementioned regions
  • Ophthalmic Drugs submarket forecasts from 2020-2027 covering the market by prescription, by therapeutics, and geography
  • Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to ophthalmic drugs market
  • Analysis of the key factors driving and restraining the growth of the global, regional, and country level ophthalmic drugs markets from 2020-2027
  • Competitive Landscape and market positioning of top 10 players operating in the ophthalmic drugs market

Request a full report sample @ https://www.researchcorridor.com/request-sample/?id=27561


Table of Content:


Chapter 1 Methodology and Scope


1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List and Data Sources

Chapter 2 Executive Summary


2.1 Global Ophthalmic Drugs Market - Industry Summary & Key Buying Criteria
2.2 Global Ophthalmic Drugs Market - Industry Outlook

Chapter 3 Global Ophthalmic Drugs Market Dynamics


3.1 Market Driver Analysis
3.1.1 Global rise in geriatric population pushing ophthalmology drugs
3.1.2 Technology advancement
3.1.3 Innovation giving rise to ophthalmology drugs market
3.1.4 Global increase in prevalence of eye diseases
3.1.5 Global increase in healthcare expenditure
3.2 Market Restrains Analysis
3.2.1 Major drugs going off patent is affecting the growth of ophthalmology market
3.2.2 Drying pipelines is a concern for major players
3.3 Key Opportunities Prioritized
3.3.1 Increasing awareness
3.3.2 Emerging markets
3.4 Global Ophthalmic Drugs Industry Value Chain Analysis
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment, by Key Players: Global ophthalmic drugs market

Chapter 4 Global Ophthalmic Drugs Market, by Prescription Type, 2018-2027 ($ Million)


4.1 Global Prescription Market for Ophthalmic Drugs, 2018-2027 ($ Million)
4.2 Global OTC (Over the Counter) Drugs Ophthalmic Drugs Market 2018-2027 ($ Million)

Chapter 5 Global Ophthalmic Drugs Market, by Therapeutic Type, 2018-2027 ($ Million)


5.1 Global Glaucoma Ophthalmic Drugs, 2018-2027 ($ Million)
5.2 Global Retinal Disorder Ophthalmic Drugs Market 2018-2027 ($ Million)
5.3 Global Dry Eye Ophthalmic Drugs Market, 2018-2027 ($ Million)
5.4 Global Allergic Conjunctivitis Ophthalmic Drugs Market 2018-2027 ($ Million)

Chapter 6 Global Wound Care Market, by Geography, 2018-2027 ($ Million)


6.1 Overview
6.2 North America
6.2.1. U.S.
6.2.2. Canada
6.3 Europe
6.3.1. U.K.
6.3.2. Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1. Japan
6.4.2. China
6.4.3. Rest of Asia Pacific
6.5 Latin America
6.5.1. Brazil
6.5.2. Mexico
6.5.3. Rest of Latin America
6.6 Middle East and Africa
6.6.1. GCC
6.6.2. Rest of Middle East and Africa

Chapter 7 Company Profiles


7.1 Abbott Healthcare
7.2 Allergan Plc
7.3 Akorn
7.4 Bayer Johnson & Johnson
7.5 Cipla Pharmaceuticals Bayer
7.6 Eyemed
7.7 Eyegate Pharmaceuticals
7.8 Johnson & Johnson
7.9 LPath
7.10 Merck & Co.
7.11 Novartis AG
7.12 Pfizer, Inc.
7.13 Senju Pharmaceutical Co., Ltd
7.14 Senten Pharmaceutical Co. Ltd
7.15 Sun Pharmaceutical Industries, Ltd.
7.16 Valeant Pharmaceuticals, Inc.

(Reports will be updated due to COVID-19 impacts on the market)

Request Report Sample
Inquiry Before Buying
Fill the given form to request sample for Ophthalmic Drugs Market Report

Your Designtaion (required):

Fill the given form to inquiry before buying for Ophthalmic Drugs Market Report

Your Designtaion (required):

Select License Type
$3200/- Single User License
$4800/- Multi User License
$6400/- Corporate License

Why To Choose Us:
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client base has an annual subscription membership
  • 24x7 availability we are always there when you need us
  • 100,000+ data points in our comprehensive database
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report
For Any Assitance
Call Us: +919893685690
Contact Person: Mr. Vijendra Singh
Contact Email: sales@researchcorridor.com